BrightSpring Health Services, Inc. research snapshot
BTSG AI stock analysis reads BrightSpring Health Services as a company in a strong operating phase whose stock just re-priced after a beat-and-raise quarter. Q2 2026 revenue rose 23% to $3.873 billion and adjusted EBITDA rose 44% to $206 million, and the company raised 2026 revenue guidance to $15.100 billion to $15.425 billion and adjusted EBITDA guidance to $820 million to $845 million. Leverage fell to 2.15x and both Moody's and S&P upgraded the credit rating. The stock still fell about 18% on July 31, 2026, a sell-the-news reaction tied to pharmacy gross margin questions and a valuation that had roughly tripled in a year. The analysis is scenario-based: the upside case needs durable specialty pharmacy and home health growth plus margin expansion, while the downside case is tied to reimbursement and IRA pressure, thin GAAP margins, KKR selling, and a technical break below support.
Current price
$59.71
Market cap
$11.79 billion calculated from 197.5 million shares, with a $12.52 billion StockAnalysis reference on a higher share count
AI score
60 / 100
Rating
Improving growth and falling leverage, but a stretched valuation met a sharp post-earnings selloff
Trend status
Long-term uptrend still holds above the 200-day average near $46.64, but the stock broke below its 50-day average near $66.00 after a July 31 selloff and RSI is near 35
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BrightSpring delivers pharmacy and provider care for complex populations in home and community settings, with recurring medical need and strong continuing-operations growth: Q2 2026 revenue up 23% and adjusted EBITDA up 44%. | High |
| Moat | The moat comes from national pharmacy and provider scale, specialized specialty and infusion operations, 155 limited distribution drug programs, payor and referral relationships, and home health density. It is not a software platform, so reimbursement formulas, PBM contracts, and labor remain competitive pressure points. | Medium |
| Management | Management cut leverage to 2.15x, refinanced at a lower spread, bought back shares, divested Community Living, and earned credit upgrades from Moody's and S&P, while staying disciplined on M&A. | Medium-high |
| Financial trend | H1 2026 revenue was $7.487 billion, up 24%, with adjusted EBITDA of $395 million, up 45%. 2026 guidance was raised to revenue of $15.100 billion to $15.425 billion and adjusted EBITDA of $820 million to $845 million. | High |
| Valuation | At $59.71 and about 197.5 million shares, market cap is near $11.8 billion. Trailing P/E is roughly 32x on $365.97 million GAAP TTM net income, while feeds using other earnings bases show 49x to 59x. Forward P/E is near 30x to 35x on 2026 adjusted EPS around $1.69, with price-to-sales near 0.8x to 0.9x. | Medium |
| Technical trend | The intermediate trend is under pressure after the -18% July 31 drop. Price sits below the 50-day average near $66.00 but above the 200-day near $46.64, with RSI near 35. | Medium-low |
| Risk level | Main risks are Medicare and Medicaid reimbursement changes, the IRA revenue and EBITDA headwind, PBM contract pressure, potential generic tariffs, labor costs, KKR secondary selling, acquisition integration, thin GAAP margins, and a high-volatility chart. | High |
| AI confidence | Data confidence is high for reported operating results and medium for forward price paths because the stock just re-priced sharply and multiple feeds disagree on trailing earnings bases. | High data confidence |
| Investment certainty | BTSG is an improving growth platform with a cleaner balance sheet, but certainty is limited until pharmacy gross margin stabilizes, the market re-tests support, and free cash flow evidence catches up with the growth story. | Medium-low |
BTSG AI stock forecast
The BTSG AI stock forecast is scenario-based around the $59.71 price reference. A three-scenario earnings and multiple model, built on 2026 consensus adjusted EPS of about $1.69, produced a bearish area near $40 to $52, a base area near $62 to $74, and a bullish area near $80 to $100 over roughly two years, before future capital allocation or share count effects.
$80 to $100
More likely if specialty pharmacy and infusion keep double-digit growth, LDD and oncology-to-rare-orphan wins continue, home health integration lifts Provider margins, adjusted EBITDA margins expand, leverage stays below 2x, and the market holds a low-30s to high-30s forward multiple as EPS compounds.
$62 to $74
More likely if revenue grows near the guidance range, adjusted EBITDA rises toward $820 million to $845 million, GAAP net margins stay thin, IRA and reimbursement pressure stay contained, and the multiple settles near 30x to 35x on 2027 EPS.
$40 to $52
More likely if pharmacy gross margin keeps sliding, IRA or Part D reimbursement effects worsen, generic tariffs or PBM pressure hit specialty economics, KKR selling overwhelms demand, guidance is cut, or the multiple compresses toward the low 20s on stalled EPS.
BTSG AI technical analysis
BTSG AI technical analysis turned more cautious after the July 31, 2026 selloff. Price closed at $59.71 after falling about 18% on heavy volume, moving below the 50-day average near $66.00 while staying above the 200-day average near $46.64. The 52-week range is $19.01 to $73.75, and Barchart levels put first support near $55.96, second near $52.22, and third near $45.17, with resistance at $66.75, $73.80, and $77.54. RSI was near 35 and short interest was about 4.8% of shares out.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $59.71 close on July 31, 2026, after-hours $60.38 | StockAnalysis real-time close and Barchart reference as of the August 3, 2026 data cutoff. |
| Immediate support | $55.90 to $56.30 | Barchart first support near $55.96. A hold here would suggest the post-earnings flush is contained. |
| Secondary support | $52.20 to $52.90 | Barchart second support near $52.22 and a Fibonacci 61.8% retracement near $52.84 from the $19.01 to $73.75 range. |
| Deep support | $45.00 to $47.00 | Fibonacci 50% near $46.38 and Barchart third support near $45.17. This zone would mark a serious trend repair failure. |
| Near resistance | $66.75 to $67.00 | Barchart first resistance near $66.75, near the broken 50-day average around $66.00. Reclaiming it would restore short-term structure. |
| Major resistance | $73.75 to $73.80 | The July 27, 2026 52-week high near $73.75 and Barchart second resistance near $73.80 form the major supply zone. |
| Moving averages | 50-day near $66.00, 200-day near $46.64 | StockAnalysis moving average snapshot as of August 2, 2026. Price is below the 50-day but above the 200-day. |
| Momentum | RSI near 34.89 | StockAnalysis RSI as of August 2, 2026, down sharply from overbought territory and pointing to weak short-term momentum. |
| Volume and volatility | Volume about 7.7 million shares on July 31 versus a 4.6 million 20-day average; options implied volatility near 52% | The selloff came on roughly 1.7x the average volume, and the 19-day expected options range was roughly $54.98 to $64.44 on Barchart. |
| Invalidation | Close below $52.20 | A close below the $52.20 area would shift the setup toward the $45 to $47 support zone and signal a deeper correction after the re-rating. |
BTSG AI trading strategy
The BTSG AI trading strategy below is a rules-based research framework, not personal advice. It links BrightSpring operating momentum, reimbursement and IRA updates, KKR selling, leverage, and technical confirmation with predefined invalidation levels after the July 31 price break.
Wait for BTSG to reclaim $66.75 and hold above the 50-day average with expanding volume after the post-earnings flush. Confirmation should include stable or raised guidance, no new reimbursement shock, and continued Pharmacy and Provider growth.
A rally that stalls below $66.75 and rolls over again would keep the setup on hold because it would show the market still working through valuation concerns.
If BTSG holds $55.90 to $56.30 and shows a stabilizing RSI near 35 with easing volume, compare the reaction with analyst revisions, pharmacy gross margin commentary, specialty pharmacy and home health updates, and free cash flow releases.
Do not treat the pullback as benign if price closes below $52.20 or if management cuts 2026 revenue or adjusted EBITDA guidance, because that would confirm the earnings reset was more than technical.
Track Q3 2026 revenue, Pharmacy versus Provider mix, gross profit per script, adjusted EBITDA, GAAP net income, free cash flow, leverage, KKR or management secondary sales, the Community Living settlement effects, and Medicare or Part D policy changes.
Position sizing should reflect reimbursement and IRA risk, thin GAAP margins, KKR ownership overhang, elevated volatility, and the sharp July 31 move.
Investment research summary
BrightSpring is paid to deliver pharmacy and provider care for complex patients in home and community settings, serving over 485,000 customers daily. Payors, hospitals, ACOs, and manufacturers fund it because specialty drugs, infusion, home health, rehab, and personal care can be delivered at lower cost outside higher-cost facilities while still meeting clinical need.
The moat is strongest in national scale, specialized pharmacy operations with 155 limited distribution drug programs, payor and referral relationships, clinical staffing density, and the ability to bundle pharmacy with provider services. It is weaker where competitors bid for the same PBM or Medicaid contracts or where reimbursement formulas compress gross profit.
The thesis fails if pharmacy gross margin keeps falling, IRA or Part D reimbursement cuts hit specialty economics, generic tariffs or PBM pressure compress drug margins, acquisitions like the Amedisys and LHC branches fail to integrate, labor costs outrun pricing, KKR selling overwhelms demand, or investors decide thin GAAP earnings no longer support a growth multiple.
Management under CEO Jon Rousseau and CFO Jen Phipps grew continuing-operations revenue 24% in the first half, cut leverage to 2.15x, refinanced at a lower spread, repurchased stock, divested Community Living, and earned upgrades from Moody's to Ba3 and S&P to BB-. The open question is whether capital allocation keeps converting scale into durable free cash flow.
The long-term trend favors lower-cost care settings as aging populations, chronic disease, specialty drug utilization, and payor cost pressure push care into the home. Offsets include policy risk, IRA and PBM pressure, labor shortages, and consolidation among payors and large home health competitors.
At $59.71, BTSG still carries about $11.8 billion in market cap after a roughly 180% 52-week run, with a forward P/E near 30x to 35x and thin GAAP margins. Margin of safety is limited unless EPS compounds toward the low-to-mid $2 range while the multiple holds.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $59.71 close on July 31, 2026, after-hours $60.38, down 18.07% on the day | StockAnalysis BTSG quote | August 3, 2026 |
| Shares outstanding | 197,509,491 shares issued and outstanding at June 30, 2026 per the 10-Q; Barchart about 197.3 million | BrightSpring Form 10-Q and Barchart quote | August 3, 2026 |
| Market capitalization verification | $11.79 billion calculated from $59.71 x 197.5 million shares, matching Barchart near $11.78 billion; StockAnalysis reports $12.52 billion using a higher 209.6 million share count | Pineify financial_rigor.py, Barchart, and StockAnalysis statistics | August 3, 2026 |
| Q2 2026 revenue and earnings | Revenue $3.873 billion up 23.0%, gross profit $493 million up 31.5%, net income $87 million, adjusted EBITDA $206 million up 44.2%, adjusted EPS $0.45 | BrightSpring Q2 2026 earnings release | July 31, 2026 |
| Q2 2026 segment revenue and EBITDA | Pharmacy Solutions revenue $3.407 billion up 22% and segment EBITDA $180 million up 44%; Provider Services revenue $466 million up 30% and segment EBITDA $75 million up 33% | BrightSpring Q2 2026 earnings release segment table | July 31, 2026 |
| H1 2026 revenue and adjusted EBITDA | Revenue $7.487 billion up 24%, adjusted EBITDA $395 million up 45% | BrightSpring Q2 2026 earnings release | July 31, 2026 |
| FY2026 guidance | Revenue $15.100 billion to $15.425 billion and adjusted EBITDA $820 million to $845 million, excluding Community Living and future closed acquisitions | BrightSpring Q2 2026 earnings release | July 31, 2026 |
| Leverage and balance sheet | Leverage 2.15x at June 30, 2026; cash $550.4 million, total debt about $2.4 billion including leases; net debt about $1.7 billion per management | BrightSpring Q2 2026 earnings release and StockAnalysis statistics | July 31, 2026 |
| Credit rating upgrades | Moody's upgraded to Ba3 from B1 and S&P upgraded to BB- from B+ during Q2 2026 | BrightSpring Q2 2026 earnings call transcript | July 31, 2026 |
| TTM financials | TTM revenue about $14.37 billion, TTM net income about $365.97 million, free cash flow about $402 million | StockAnalysis statistics | August 2, 2026 |
| Valuation multiples | Trailing P/E about 32x on GAAP TTM net income but 49x to 59x on source TTM EPS bases; forward P/E near 30x to 35x on 2026 adjusted EPS about $1.69; price-to-sales about 0.82x to 0.87x; price-to-book about 6.1x | Pineify financial_rigor.py, StockAnalysis statistics, and Barchart fundamentals | August 2, 2026 |
| Analyst consensus and targets | Consensus Strong Buy from 18 analysts, average target $78.53, range $58 to $90; Mizuho reiterated Outperform at $86 on July 31, 2026 | StockAnalysis forecast page | July 31, 2026 |
| Technical moving averages and RSI | 50-day average near $66.00, 200-day average near $46.64, RSI near 34.89 | StockAnalysis statistics | August 2, 2026 |
| Technical turning points | Barchart support $55.96 / $52.22 / $45.17 and resistance $66.75 / $73.80 / $77.54; Fibonacci 61.8% near $52.84 and 50% near $46.38 | Barchart trader cheat sheet | August 3, 2026 |
This BTSG AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of August 3, 2026 and can be wrong if earnings, guidance, reimbursement, IRA or Part D policy, specialty pharmacy economics, leverage, ownership sales, interest rates, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
